


# THE SOLUTION FOR PATIENTS AT RISK OF HIP FRACTURE




PROXIMAL FEMUR SYSTEM



A STRUTPLASTY TECHNIQUE FOR BONE CONSOLIDATION

www.hypreventionusa.com




### **PRODUCT DESCRIPTION**

- Implantable medical device composed of 2 implants connected in situ, made of radio-transparent PEEK polymer
- Range of sizes to fit patient's anatomy
- Combined with PMMA bone cement
- Bone reinforcement<sup>14</sup>

# HIP FRACTURE : A GLOBAL HEALTH ISSUE

# More than 2 million hip fractures annually worldwide, over 6 million in 2050<sup>1,2</sup> with growing and aging population



Surgical prevention : a potential solution to avoid contralateral hip fracture with associated morbidity and costs<sup>6,7</sup>




# TRAUMATOLOGY INDICATION

STRUT is indicated for **contralateral** percutaneous internal fixation of proximal femur, in osteoporotic patients with a low energy pertrochanteric fracture on the first side

- Same surgical time for the fracture treatment and the contralateral procedure or prophylactic surgery in a second time (within 120 days after the fracture treatment)
- Clinical experience<sup>15,16</sup>:

1<sup>st</sup> patient in February 2013




# HIP FRACTURE : A GLOBAL HEALTH ISSUE

# 25% of metastatic bone lesions occurs in the proximal femur, patients at high risk of pathological fractures<sup>8</sup>

 Bone is the third location of metastases after the lungs and liver. The origin of lytic bone metastases varies and is often linked to a primary tumour of the thyroid, kidney, lung or breast<sup>8</sup>

ONCOLOGY

 Severe consequences of pathological fractures : patients' life
expectancy affected and loss of quality of life<sup>9</sup>



Bone metastasis incidence per type of cancer<sup>11,12,13</sup>

Various surgical techniques, like standard osteosynthesis fixation, are being performed to treat lytic bone lesions, prevent these fractures and improve patients' quality of life<sup>10</sup>

# **ONCOLOGY INDICATION**

VSTRUT is indicated for percutaneous internal fixation for **impending pathological fracture** of proximal femur - act of last resort (ultima ratio)

- Minimally invasive procedure allows to continue the chemotherapy treatment
- Short hospitalization duration (mean 2.3 days)
- PEEK polymer material allows local radiotherapy
- Clinical experience<sup>15,17</sup>:

 $1^{st}$  study completed in 2016 on  ${\bf 10}$  patients followed during 1 year





# STRUT

# REFERENCES

- 1. Cooper et al. Osteoporos Int. 1992 Nov; 2(6):285-9
- 2. http://www.indexmundi.com
- 3. Ryg et al. J Bone Miner Res. 2009 Jul; 24(7):1299-307
- 4. Keene et al. BMJ. 1993; 307:1248
- 5. Melton III et al. Osteoporos Int. 2003; 14: 383-388
- 6. Giannini et al. Clin Cases Miner Bone Metab. 2011;8(1):51-54
- 7. Ferrari et al. Arch Osteoporos. 2016;11(1):37
- 8. Hage et al. Orthop Clin North Am. 2000; (31):515-528
- 9. Harvey et al, Clin Orthop Relat Res. 2012 Mar; 470(3):684-91
- 10. Arvinius et al. Int Orthop. 2014; 38:129-132
- 11. Coleman. Clin Cancer Res. 2006;12:6243s-6249s
- 12. http://globocan.iarc.fr
- 13. Kenan et al. Cancer Medicine. 6e 2003. pp. 2477-9
- 14. Szpalski et al. Clin Biomech. 2015 Aug; 30(7):713-9
- 15. Cornelis et al. J Orthop Surg Res. 2017 Feb 9;12(1):27
- 16. Szpalski et al. J Osteopor Phys Act. 2017; 5:2 DOI: 10.4172/2329-9509.1000202
- 17. Cornelis et al. Cardiovasc Intervent Radiol. 2017 Jul;40(7):1070-1076
- 18. Reynders-Frederix P et al. Bioceram Dev Appl 2018, 8:1
- 19. Reynders-Frederix P et al. Acta Ortho Belgica, 2022 Mar;88(1):11-16

prevention®

### www.hypreventionusa.com

USA 1411 Broadway FI 16 usa@hyprevention.com T. +1 (772) 228 3218 Medical device For more information, see the instructions for use

PATENTED Licensed in Brazil Granted Breakthrough Device by the FDA (Not FDA cleared, not CE marked)



PLA-HYP01-EN V08